
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ ® Named Early Access Program (AAC) in France
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ ® upon approval of a dose-ranging clinical study.
Clear Path Forward for LUMEVOQ ® AAC Program in France
Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025.
In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest.
"In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics."We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment."
Financing Strategy to Support Regulatory Milestones
GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones.
' We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study,' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities."
Advancing Core Marketing Authorization Strategy
In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy:
Preparation for regulatory consultations in the US and EU
Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements
Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply
Advancing preparations for MHRA submission in the United Kingdom
During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities.
Multiple Value Catalysts
GenSight anticipates a number of significant value-creating events in 2025-2026:
Financial Position
The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025.
The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ ®.
As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares.
Risk factors
Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website (www.gensight-biologics.com) and/or AMF (www.amf-france.org). The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the Company's future,' said Stanley M. Bergman. 'With the progress made advancing our BOLD+1 strategic plan and with strong management in place, it is the right time for me to retire at the end of the year,' Mr. Bergman said. 'I look forward to working with the Board to identify my successor and effect a smooth transition. Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the Company's future.' Philip A. Laskawy, Lead Director for Henry Schein said, 'Under Stan's leadership, Henry Schein has become the global leader in providing dental and medical products and solutions for health care providers in alternate care settings, and we recognize the significant impact he has had on the Company and the entire health care industry. We owe a tremendous debt of gratitude to Stan for his steadfast devotion to Henry Schein and for bringing his unique blend of strategic vision, attention to detail, and entrepreneurship to the Company.' During Mr. Bergman's tenure as CEO, Henry Schein's revenue grew from $225 million in 1989 to almost $13 billion in 2024, representing an approximate compound annual growth rate of 17.5%, while the Company's market capitalization grew from $290 million at the time of its IPO in 1995 to a current value of almost $9 billion 1. Further, Henry Schein has delivered a non-GAAP EPS CAGR of 12.4% over this same period 2. Among Mr. Bergman and the team's many accomplishments, the Company transformed itself multiple times: growing from what was a small, U.S.-based primarily dental mail order company to becoming the largest global full service dental distributor of products and services and a leading medical distributor to alternate care sites with a growing presence in home-delivered products; building what is now the largest provider of global dental practice management software and digital services; creating a fast-growing dental specialties business, including the 2 nd -largest provider of endodontic products and 3 rd -largest provider of dental implant and bone regeneration products; significantly growing the contribution from its higher growth, higher margin businesses and corporate-brand products under its BOLD+1 strategic plan to over 50% of total non-GAAP operating income 3; and establishing Henry Schein as a global leader in advancing public-private partnerships to support access to care for underserved individuals, strengthening infrastructure for disaster relief and pandemic preparedness, and elevating the role of oral health as a key part of systemic health and wellness. 'It has been my greatest privilege to lead Team Schein over the past 35-plus years. Guided by our purpose-driven mission, we have built an agile Company that is able to meet the changing needs of our customers, has created significant shareholder value, and is well positioned for the future. As part of succession planning, the Company has focused on developing the next generation of leaders and earlier this year simplified the business by separating into three operating divisions, each with outstanding leadership. I fully expect that Andrea Albertini, CEO of the Global Distribution Group who also has responsibility for the Global Technology Group, and Tom Popeck, CEO of the Health Care Specialties Group, together with the rest of the Company's Executive Management Committee, will elevate Henry Schein to new heights by continuing to advance the BOLD+1 strategy and working with KKR on value creation initiatives and a broad-based employee ownership program,' Mr. Bergman said. Mr. Bergman sent out a letter this morning in which he thanked all of Team Schein for playing such an important part of building a unique company. He wrote in part: 'I am especially pleased to have worked with tens of thousands of incredibly committed and talented Team Schein Members who helped reimagine and reinvent Henry Schein's role, from one of product delivery and logistics to one whose mission today is to help our over 1 million health care professionals operate better and more efficient practices so our customers can concentrate on delivering the best quality patient care.' Mr. Bergman concluded his letter by thanking many people who stood by his side during the journey, including senior management, the Board, the Schein family, and others. 'With the team continuing to balance the Company's five constituents that make up the Henry Schein Mosaic of Success (suppliers, customers, investors, employees, and society at large) and maintaining the values of Team Schein, I believe that Henry Schein's best years are yet to come,' Mr. Bergman continued. About Henry Schein, Inc. Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at and @HenrySchein on X. Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as 'may,' 'could,' 'expect,' 'intend,' 'believe,' 'plan,' 'estimate,' 'forecast,' 'project,' 'anticipate,' 'to be,' 'to make' or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; our ability to develop or acquire and maintain and protect new products (particularly technology products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, changes to other economic indicators and international trade agreements; the threat or outbreak of war, terrorism or public unrest (including, without limitation, the war in Ukraine, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions, including the current imposition of additional new tariffs by the U.S. on numerous countries, retaliatory tariffs and potential for additional retaliatory tariffs; greater restrictions on imports and exports; supply chain disruption; geopolitical wars; failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law. Included within the press release are non-GAAP financial measures that supplement the Company's Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company's actual results prepared under GAAP to exclude certain items. In the schedule attached to the press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs, and amortization of acquisition-related assets, because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Exhibit * Average annual increase (1) In 1995, Operating Income, Net Income and Diluted EPS were negative, and CAGR amounts cannot be calculated. Using 1996 as a base year the CAGR for Operating Income, Net Income and Diluted EPS was 15.08%, 17.15%, and 14.23%, respectively. For 1996, there we no reconciling items on a GAAP to Non-GAAP basis. Note: Amounts may not sum due to rounding. Expand ___________________________ 1 This excludes the Company's 2019 spin-off of its animal health business to a separate publicly held company which had an initial market capitalization of over $4 billion. 2 From Continuing Operations, based on 12-month data through Q4 2024. Excludes certain non-recurring items to provide a more comparable basis for analysis. A reconciliation of GAAP to non-GAAP adjustments is included as an Exhibit to this press release. CAGRs are calculated as of December 28, 2024. 3 The Company is unable to calculate the GAAP operating income contribution without unreasonable effort, so it is not including it in the reconciliation. Expand Expand


Scientific American
an hour ago
- Scientific American
Doctors Discover a Woman With Her Own Unique Blood Type
The following essay is reprinted with permission from The Conversation, an online publication covering the latest research. In a routine blood test that turned extraordinary, French scientists have identified the world's newest and rarest blood group. The sole known carrier is a woman from Guadeloupe whose blood is so unique that doctors couldn't find a single compatible donor. The discovery of the 48th recognised blood group, called 'Gwada-negative', began when the woman's blood plasma reacted against every potential donor sample tested, including those from her own siblings. Consequently, it was impossible to find a suitable blood donor for her. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Many people know their blood type – A, B, AB or O – along with whether they are Rh-positive or negative. But these familiar categories (those letters plus 'positive' or 'negative') represent just two of several dozens of blood group systems that determine compatibility for transfusions. Each system reflects subtle but crucial differences in the proteins and sugars coating our red blood cells. To solve the mystery of the Guadeloupian woman's incompatible blood, scientists turned to cutting-edge genetic analysis. Using whole exome sequencing – a technique that examines all 20,000-plus human genes – they discovered a mutation in a gene called PIGZ. This gene produces an enzyme responsible for adding a specific sugar to an important molecule on cell membranes. The missing sugar changes the structure of a molecule on the surface of red blood cells. This change creates a new antigen – a key feature that defines a blood group – resulting in an entirely new classification: Gwada-positive (having the antigen) or -negative (lacking it). Using gene editing technology, the team confirmed their discovery by recreating the mutation in a lab. So red blood cells from all blood donors tested are Gwada-positive and the Guadeloupean patient is the only known Gwada-negative person on the planet. The implications of the discovery extend beyond blood transfusions. The patient suffers from mild intellectual disability, and tragically, she lost two babies at birth – outcomes that may be connected to her rare genetic mutation. The enzyme produced by the PIGZ gene operates at the final stage of building a complex molecule called GPI (glycosylphosphatidylinositol). Previous research has shown that people with defects in other enzymes needed for GPI assembly can experience neurological problems ranging from developmental delays to seizures. Stillbirths are also common among women with these inherited disorders. Although the Caribbean patient is the only person in the world so far with this rare blood type, neurological conditions including developmental delay, intellectual disability and seizures have been noted in other people with defects in enzymes needed earlier in the GPI assembly line. The Gwada discovery highlights both the marvels and challenges of human genetic diversity. Blood groups evolved partly as protection against infectious diseases (many bacteria, viruses and parasites use blood group molecules as entry points into cells). This means your blood type can influence your susceptibility to certain diseases. But extreme rarity creates medical dilemmas. The French researchers acknowledge they cannot predict what would happen if Gwada-incompatible blood were transfused into the Guadeloupian woman. Even if other Gwada-negative people exist, they would be extremely difficult to locate. It is also unclear if they can become blood donors. This reality points towards a futuristic solution: lab-grown blood cells. Scientists are already working on growing red blood cells from stem cells that could be genetically modified to match ultra-rare blood types. In the case of Gwada, researchers could artificially create Gwada-negative red blood cells by mutating the PIGZ gene. A growing field Gwada joins 47 other blood group systems recognised by the International Society of Blood Transfusion. Like most of these blood-group systems, it was discovered in a hospital lab where technicians were trying to find compatible blood for a patient. The name reflects the case's Caribbean roots: Gwada is slang for someone from Guadeloupe, giving this blood group both scientific relevance and cultural resonance. As genetic sequencing becomes more advanced and widely used, researchers expect to uncover more rare blood types. Each discovery expands our understanding of human variation and raises fresh challenges for transfusion and other types of personalised medicine.


Business Wire
an hour ago
- Business Wire
Wells Fargo Reports Second Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Wells Fargo & Company (NYSE: WFC) has released its second quarter 2025 financial results. The financial results are available online at and on a Form 8-K filed by the company with the Securities and Exchange Commission (SEC) on July 15, 2025, and available on the SEC's website at Conference call The company will host a live conference call on Tuesday, July 15, at 10:00 a.m. Eastern time. You may listen to the call by dialing 1-888-673-9782 (U.S. and Canada) or 312-470-7126 (International/U.S. Toll) and entering passcode: 8320644#. The call will also be available online at A replay of the conference call will be available from approximately 1:00 p.m. Eastern time on July 15 through Tuesday, July 29. Please dial 1-866-360-7722 (U.S. and Canada) or 203-369-0174 (International/U.S. Toll) and enter passcode: 6786#. A webcast replay will also be available online at About Wells Fargo Wells Fargo & Company (NYSE: WFC) is a leading financial services company that has approximately $2.0 trillion in assets. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth & Investment Management. Wells Fargo ranked No. 33 on Fortune's 2025 rankings of America's largest corporations. News, insights, and perspectives from Wells Fargo are also available at Wells Fargo Stories. News Release Category: WF-CFH